The Trump administration moved on Thursday to reclassify medical marijuana from Schedule I to Schedule III under the Controlled Substances Act - and within hours, the Treasury Department and IRS announced they intend to issue new guidance spelling out what that means for taxes. For state-licensed medical cannabis operators, the implications are immediate and significant: relief from Section 280E of the tax code, a provision that has long forced marijuana businesses to pay federal income tax on gross revenue rather than profit, with no deductions for ordinary business expenses.
What 280E Actually Does - and Why Removing It Matters
Section 280E exists because of a 1980s-era legal interpretation: businesses trafficking in Schedule I or II controlled substances cannot deduct routine operating expenses under federal tax law. Rent, payroll, utilities - none of it. The result is that cannabis companies have been taxed on a basis that no other legal industry faces, often paying effective federal tax rates that make profitability difficult even when state-level operations are running well. Rescheduling to Schedule III takes cannabis out of that framework entirely, at least for the medical side.
The IRS and Treasury were explicit: rescheduling "generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances." That is a material financial shift. Not incremental. For operators in state medical markets who have been structuring their finances around 280E for years, this changes the underlying economics of the business.
The Catch - Recreational Markets Stay in Schedule I, For Now
Here's where it gets complicated. Acting Attorney General Todd Blanche's order moves state-licensed medical cannabis immediately to Schedule III. Recreational cannabis - the larger market by revenue in most states that have legalized it - remains Schedule I, pending a formal hearing process expected this summer. That bifurcation creates an unusual situation for the many multi-state operators and dispensaries that serve both markets under the same roof.
Treasury and the IRS acknowledged the problem directly, noting that guidance will "clarify the ways in which, for businesses with multiple activities, section 280E applies only to those activities related to trafficking in Schedule I or II controlled substances - by apportioning expenses." In practice, that means cannabis companies straddling both medical and recreational sales will need to account for their operations in two separate tax categories, at least temporarily. How that apportionment works in practice - which expenses go where, and how mixed-use facilities get treated - is precisely what the forthcoming guidance is supposed to resolve. The agencies did not say when that guidance would arrive.
Retrospective Relief Is on the Table, but Far From Guaranteed
Blanche's order explicitly encouraged Treasury Secretary Scott Bessent to consider "retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license." That is, potentially, a reversal of years of excess taxation. The industry has sought this kind of relief for a long time. But the IRS announcement was measured: it addressed only what it called a "transition rule" going forward, describing rescheduling as applying to the full taxable year that includes the effective date of the final order. Past years are a separate question, and the agencies offered no commitment on that front.
What's striking here is the gap between the DOJ's language - which encourages retrospective relief - and Treasury's more cautious framing. Encouragement is not a mandate. Whether cannabis businesses receive retroactive tax adjustments will likely depend on whatever guidance eventually emerges and, in some cases, on litigation.
Rescheduling Is Not Legalization - and the Gun Rights Wrinkle Remains
Worth stating plainly: rescheduling cannabis to Schedule III does not federally legalize it. Possession, sale, and distribution remain federal offenses under the CSA for Schedule III substances - just with different penalties and regulatory implications than Schedule I. The distinction matters for banking access, interstate commerce, employment law, and federal contracting. None of those issues are resolved by Thursday's action.
Separately, the Justice Department filed a brief with the Supreme Court on the same day, arguing that rescheduling does not change how the Court should rule in a pending case involving cannabis consumers' Second Amendment rights. Federal law prohibits firearms possession by unlawful drug users, and the DOJ's position is that cannabis consumers - regardless of rescheduling - remain in that category. The administration, in other words, is moving cannabis in one direction on taxes while holding its ground on gun rights. President Trump, for his part, spoke briefly in the Oval Office about marijuana's medical utility - "a lot of people are suffering from big problems, which this seems to be the best answer" - without addressing either the tax mechanics or the gun rights question directly.
For the cannabis industry, Thursday was a meaningful day. But the guidance still needs to be written, the hearing on recreational rescheduling still needs to happen, and the full shape of what this administration will ultimately do with cannabis policy remains, at this point, an open question.
